Logo image of ORKA

ORUKA THERAPEUTICS INC (ORKA) Stock Fundamental Analysis

NASDAQ:ORKA - Nasdaq - US6876041087 - Common Stock - Currency: USD

14.54  -0.82 (-5.34%)

After market: 14.54 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ORKA. ORKA was compared to 558 industry peers in the Biotechnology industry. ORKA has a great financial health rating, but its profitability evaluates not so good. ORKA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ORKA had negative earnings in the past year.
In the past year ORKA has reported a negative cash flow from operations.
In the past 5 years ORKA always reported negative net income.
ORKA had a negative operating cash flow in each of the past 5 years.
ORKA Yearly Net Income VS EBIT VS OCF VS FCFORKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -27.77%, ORKA is doing good in the industry, outperforming 70.25% of the companies in the same industry.
The Return On Equity of ORKA (-28.71%) is better than 79.57% of its industry peers.
Industry RankSector Rank
ROA -27.77%
ROE -28.71%
ROIC N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ORKA Yearly ROA, ROE, ROICORKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ORKA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORKA Yearly Profit, Operating, Gross MarginsORKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ORKA has more shares outstanding
Compared to 5 years ago, ORKA has more shares outstanding
ORKA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORKA Yearly Shares OutstandingORKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ORKA Yearly Total Debt VS Total AssetsORKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ORKA has an Altman-Z score of 27.56. This indicates that ORKA is financially healthy and has little risk of bankruptcy at the moment.
ORKA's Altman-Z score of 27.56 is amongst the best of the industry. ORKA outperforms 95.88% of its industry peers.
There is no outstanding debt for ORKA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.56
ROIC/WACCN/A
WACCN/A
ORKA Yearly LT Debt VS Equity VS FCFORKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ORKA has a Current Ratio of 30.03. This indicates that ORKA is financially healthy and has no problem in meeting its short term obligations.
ORKA has a Current ratio of 30.03. This is amongst the best in the industry. ORKA outperforms 97.31% of its industry peers.
A Quick Ratio of 30.03 indicates that ORKA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 30.03, ORKA belongs to the top of the industry, outperforming 97.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 30.03
Quick Ratio 30.03
ORKA Yearly Current Assets VS Current LiabilitesORKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ORKA have decreased strongly by -101.20% in the last year.
EPS 1Y (TTM)-101.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORKA will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.18%
EPS Next 2Y13.84%
EPS Next 3Y8.03%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORKA Yearly EPS VS EstimatesORKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2024 2025 2026 2027 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORKA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORKA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORKA Price Earnings VS Forward Price EarningsORKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORKA Per share dataORKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.84%
EPS Next 3Y8.03%

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 11.09%, ORKA is a good candidate for dividend investing.
ORKA's Dividend Yield is rather good when compared to the industry average which is at 90.20. ORKA pays more dividend than 99.82% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, ORKA pays a better dividend.
Industry RankSector Rank
Dividend Yield 11.09%

5.2 History

ORKA does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ORKA Yearly Dividends per shareORKA Yearly Dividends per shareYearly Dividends per share 2024 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y13.84%
EPS Next 3Y8.03%
ORKA Yearly Income VS Free CF VS DividendORKA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

More info and screens

ORUKA THERAPEUTICS INC

NASDAQ:ORKA (7/18/2025, 8:02:03 PM)

After market: 14.54 0 (0%)

14.54

-0.82 (-5.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)07-30 2025-07-30
Inst Owners84.99%
Inst Owner Change0%
Ins Owners3.23%
Ins Owner Change0%
Market Cap544.38M
Analysts89.33
Price Target40.29 (177.1%)
Short Float %11.64%
Short Ratio17.74
Dividend
Industry RankSector Rank
Dividend Yield 11.09%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.02%
Min EPS beat(2)22.5%
Max EPS beat(2)29.55%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.67%
EPS NQ rev (1m)-2.94%
EPS NQ rev (3m)12.3%
EPS NY rev (1m)-0.81%
EPS NY rev (3m)11.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-5.57
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS9.74
TBVpS9.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.77%
ROE -28.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 30.03
Quick Ratio 30.03
Altman-Z 27.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)233.92%
Cap/Depr(5y)234.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
EPS Next Y36.18%
EPS Next 2Y13.84%
EPS Next 3Y8.03%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1318.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-842.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-840.16%
OCF growth 3YN/A
OCF growth 5YN/A